Zobrazeno 1 - 10
of 63
pro vyhledávání: '"David Y. Oh"'
Autor:
Elvira Mennillo, Yang Joon Kim, Gyehyun Lee, Iulia Rusu, Ravi K. Patel, Leah C. Dorman, Emily Flynn, Stephanie Li, Jared L. Bain, Christopher Andersen, Arjun Rao, Stanley Tamaki, Jessica Tsui, Alan Shen, Madison L. Lotstein, Maha Rahim, Mohammad Naser, Faviola Bernard-Vazquez, Walter Eckalbar, Soo-jin Cho, Kendall Beck, Najwa El-Nachef, Sara Lewin, Daniel R. Selvig, Jonathan P. Terdiman, Uma Mahadevan, David Y. Oh, Gabriela K. Fragiadakis, Angela Pisco, Alexis J. Combes, Michael G. Kattah
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Ulcerative colitis (UC) is driven by immune and stromal subsets, culminating in epithelial injury. Vedolizumab (VDZ) is an anti-integrin antibody that is effective for treating UC. VDZ is known to inhibit lymphocyte trafficking to the intest
Externí odkaz:
https://doaj.org/article/0ea20593138a4ffda5f1bf392dc9a45e
Autor:
Ning Zhao, Conner Bardine, André Luiz Lourenço, Yung-hua Wang, Yangjie Huang, Simon J. Cleary, David M. Wilson, David Y. Oh, Lawrence Fong, Mark R. Looney, Michael J. Evans, Charles S. Craik
Publikováno v:
ACS Central Science, Vol 7, Iss 10, Pp 1638-1649 (2021)
Externí odkaz:
https://doaj.org/article/855612b3a40e4f52a10ffc43856da1af
Autor:
Katsunobu Hagihara, Stephen Chan, Li Zhang, David Y. Oh, Xiao X. Wei, Jeffry Simko, Lawrence Fong
Publikováno v:
OncoImmunology, Vol 8, Iss 1 (2019)
Sipuleucel-T is the only FDA-approved immunotherapy for metastatic castration-resistant prostate cancer. The mechanism by which this treatment improves survival is not fully understood. We have previously shown that this treatment can induce the recr
Externí odkaz:
https://doaj.org/article/03b05b99d7c1490795f7775d00392bf0
Autor:
Lawrence Fong, Nadeem A. Sheikh, David Y. Oh, Tao He, Jason Cham, Hai Yang, Harini Kandadi, Li Zhang
Supplementary Fig. 4: (A-D) BCR convergent groups converge to shared amino acid sequences. (A-B) Phylogenetic trees across all repertories of a representative naive patient (A) and of a representative treated patient (B). For each patient, social net
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d9d81c1fee6dcaf99dcbba592fbd381
https://doi.org/10.1158/2326-6066.22543507
https://doi.org/10.1158/2326-6066.22543507
Autor:
Lawrence Fong, Nadeem A. Sheikh, David Y. Oh, Tao He, Jason Cham, Hai Yang, Harini Kandadi, Li Zhang
Supplementary Fig. 2A: Changes in rank of the top 100 BCR clones at week 2 for a representative naïve patient are shown. The top 100 clonotypes at week 2 were identified based on their abundances at week 2. The rank of those clones at other timepoin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14ef8d41f971c71cba7e91043379a971
https://doi.org/10.1158/2326-6066.22543513.v1
https://doi.org/10.1158/2326-6066.22543513.v1
Autor:
Lawrence Fong, Nadeem A. Sheikh, David Y. Oh, Tao He, Jason Cham, Hai Yang, Harini Kandadi, Li Zhang
Sipuleucel-T is an autologous cellular immunotherapy, administered as three infusions, for metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T induces T- and B-cell responses to prostatic acid phosphatase (PAP), correlating to impro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b4e38aea97137bc0a8fe4bf729cc932
https://doi.org/10.1158/2326-6066.c.6550294.v1
https://doi.org/10.1158/2326-6066.c.6550294.v1
Autor:
Lawrence Fong, Nadeem A. Sheikh, David Y. Oh, Tao He, Jason Cham, Hai Yang, Harini Kandadi, Li Zhang
Supplementary Fig. 5: Sensitivity analysis of social network analysis of the representative sipuleucel-T treated patient. (A) Density plot of the clone frequency for all clones of the treated patient (red) and density plot of the clone frequency for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::758816d491ee1bee42e0426c1aa44d8a
https://doi.org/10.1158/2326-6066.22543504.v1
https://doi.org/10.1158/2326-6066.22543504.v1
Autor:
Lawrence Fong, Nadeem A. Sheikh, David Y. Oh, Tao He, Jason Cham, Hai Yang, Harini Kandadi, Li Zhang
Selected convergent groups. (A) Illustration of the groups that are persistently present across all time points for the treated patient. (B) Illustration of the groups induced in the treated patient. (C) Illustration of the induced groups in the naiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15474e8fd0392e08246de8c71ae25910
https://doi.org/10.1158/2326-6066.22543510
https://doi.org/10.1158/2326-6066.22543510
Autor:
Lawrence Fong, Nadeem A. Sheikh, David Y. Oh, Tao He, Jason Cham, Hai Yang, Harini Kandadi, Li Zhang
Supplementary Table 2. The public clones shared between treated patients at baseline and naïve patients at post-baseline time points. The table is separated by the 5 public clones, for which, each was shared by two treated patients and two naïve pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d4bf7bbfc48cc4986029296d474d141
https://doi.org/10.1158/2326-6066.22543498.v1
https://doi.org/10.1158/2326-6066.22543498.v1
Autor:
Lawrence Fong, Nadeem A. Sheikh, David Y. Oh, Tao He, Jason Cham, Hai Yang, Harini Kandadi, Li Zhang
Study Schema. The top panel is the study schema for P101 study (treated patients) and the bottom panel is for the STRIDE study schema (naïve patients). As shown in the figure, the treated patients had received sipuleucel-T treatment on average of 8.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03c6045f56be602df3e79bfcfd62b28d
https://doi.org/10.1158/2326-6066.22543516
https://doi.org/10.1158/2326-6066.22543516